MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP-3 promoter activity via FOXP1 binding sites

Chunrong Gu1,2†, Ying Luo1,2†, Shichang Zhang1,2, Jian Xu1,2, Jiexin Zhang1,2, Huanyu Ju1,2, Jingping Liu1,2, Lixia Zhang1,2, Yan Zhang1,2, Lei Wu1,2, Erfu Xie1,2, Ting Xu1,2 & Shiyang Pan1,2

1 Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 National Key Clinical Department of Laboratory Medicine, Nanjing, China

Keywords
Invasiveness; mAb NJ001; non-small cell lung cancer; SP70 antigen; tissue inhibitor of metalloproteinase-3.

Correspondence
Shiyang Pan, Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Tel: +86 25 68303452
Fax: +86 25 68303452
Email: sypan@njmu.edu.cn

†These authors contributed equally to this work.

Received: 18 May 2020; Accepted: 9 July 2020.
doi: 10.1111/1759-7714.13593
Thoracic Cancer 11 (2020) 2630–2638

Abstract

Background: Previously, we developed a monoclonal antibody (mAb) NJ001 that binds to the antigen SP70 in human non-small cell lung cancer (NSCLC) cells and showed it could inhibit lung adenocarcinoma (AD) growth. Here, we investigated the effect and mechanisms of NJ001 in lung AD metastasis.

Methods: Human lung AD cells (SPC-A1 and A549) were treated with different concentrations of mAb NJ001, and the effects of NJ001 on cell migration and invasive activity were investigated using wound-healing and Matrigel assays, respectively. The molecular mechanism of this inhibition was explored by microarrays, qRT-PCR, western blot, luciferase assays and electrophoretic mobility shift assays (EMSA).

Results: MAb NJ001 markedly suppressed lung AD cell migration; and the invasiveness of SPC-A1 and A549 cells treated with mAb NJ001 was diminished by 65%. Tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) was highly expressed in SPC-A1 cells treated with mAb NJ001, whereas knockdown of TIMP-3 by shRNA significantly increased SPC-A1 and A549 invasiveness. MAb NJ001 affects lung AD by inhibiting TIMP-3 through direct transcriptional regulation of FOXP1 binding sites in the TIMP-3 promoter region, as shown in luciferase assays and EMSA.

Conclusions: MAb NJ001 inhibits invasiveness and metastasis in lung AD through the FOXP1 binding sites in the TIMP-3 promoter region. It may have clinical applications in preventing and treating metastatic lung AD.

Introduction

Lung cancer is the leading cause of cancer death worldwide and one of the 10 leading causes of death from all causes. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases.1 Despite great progress in surgical techniques and chemoradiation therapy in recent years, NSCLC remains an aggressive malignant tumor with a five-year survival rate of only ~15%.2, 3 The extremely poor prognosis of NSCLC is largely due to a high rate of distant metastasis after resection.

Monoclonal antibody (mAb) NJ001, which has high affinity and specificity for NSCLC cells, was generated in our laboratory.4, 5 Our previous studies showed that mAb NJ001 has effective antitumor activity both in vitro and in vivo.5 However, the effect of NJ001 on invasiveness and metastasis in lung adenocarcinoma (AD) has not yet been defined.

Tissue inhibitor of metalloproteinases (TIMPs) specifically inhibits the proteolytic activity of matrix metalloproteinases (MMPs), thus maintaining the balance of TIMPs and MMPs. TIMP-3 is a possible tumor suppressor gene, which can tightly bind to the extracellular matrix and has been shown to inhibit tumor angiogenesis, invasion, and metastasis.6, 7 Clinical studies have shown that TIMP-3 expression is decreased in many cancer types, and...
decreased expression of TIMP-3 is significantly associated with pathologic stage, nodal involvement, and poor survival in lung cancer patients.8, 9

Here, we attempted to investigate the effects of mAb NJ001 on migration and invasion in lung AD cell lines, and the underlying molecular mechanisms were explored.

Methods

Cell lines and cell culture

Human lung fibroblast cell line HFL1 and human lung cancer cell lines SPC-A1, A549, NCI-H460 and NCI-H520 were purchased from the cell bank of the Chinese Academy of Sciences in Shanghai. All cell lines were grown in RPMI 1640 medium supplemented with L-glutamine, 100 units/mL penicillin, 100 mg/mL streptomycin and 10% (v/v) fetal bovine serum (FBS) (Gibco Invitrogen, Carlsbad, CA) at 37°C in a humidified 5% CO₂ incubator. Cells were harvested for passaging or analysis using trypsin/EDTA.

Microarray analysis

SPC-A1 cells were seeded in six-well plates at 2 × 10⁶ cells per well and, after overnight incubation, cultured with or without NJ001 (300 ng/μL) for 36 hours. Total RNA was extracted from SPC-A1 cells using TRIzol (Invitrogen, Carlsbad, CA). Microarray analysis was performed using the GeneChip Human Genome 1.0 ST and the Two-Cycle Target Labeling and Control Reagents kit (Affymetrix, Santa Clara, CA) according to the manufacturers’ protocols. After hybridization of labeled mRNAs to mRNA microarrays, images were taken using an Affymetrix Gene Chip Scanner 3000. Data summarization, normalization and quality control were performed using the free mRNA QC Tool software. Comparison of samples at different times was based on the Wilcoxon rank-sum test.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Total RNA was extracted and purified from cultured cells using the Qiagen miRNeasy Mini kit (Qiagen, CA, USA) according to the manufacturer’s recommendations. Expression levels of MMP-7 and TIMP-3 were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Primers for each gene were mmp-7, forward 5'-TCGAGACTTACCGCATATTAC-3', reverse 5'-TCCA- GCGTTCATCCTCAT-3'; TIMP-3, forward 5'-CCTGTGC- GACAGGTCGGCTCT-3' reverse 5'-TCCAGAGACACT CGTTCTTG-3'. β-actin was used as an internal control, with the primers 5'-TGCGCCCAGACAAATGAA-3' and 5'-CTAAGTCATAGTCGCCCGAAGCA-3'. qPCR used the SYBR Green (TaKaRa Biotechnology Co. Ltd., Dalian, China) dye detection method on ABI StepOne Sequence Detection System under default conditions: 95°C for 10 seconds, and 40 cycles of 95°C for 5 seconds and 60°C for 34 seconds. The comparative Ct method was used to quantify the transcripts.

Western blot

For western blot analyses, cells were lysed with RIPA lysis buffer (50 mM Tris-HCl, 1% NP-40, 0.25% Na-deoxycholate, 50 mM NaCl, 1 mM EDTA, 1 mM PMSE, 1 mg/mL aprotinin, 1 mM Na₃VO₄, 1 mM NaF). Next, 25 mg of total protein was electrophoresed on a 12% SDS-PAGE gel, transferred to a PVDF membrane (Amersham Pharmacia Life Science, USA), and blocked with 10% non-fat milk in TBST. The PVDF membrane was incubated with anti-TIMP-3 (1:1000; Cell Signaling Technology, Inc., Beverly, MA, USA) and anti-GAPDH antibody (Zhongshan Biological, Beijing, China) overnight at 4°C to confirm equivalent protein loading in each lane, followed by incubation with HRP-conjugated goat-anti-rabbit IgG for one hour at room temperature, washed three times with TBST for 15 minutes each, and finally developed with ECL (Amersham Life Science) on X-ray film.

shRNA synthesis and vector construction

The TIMP-3 siRNA and a negative control (with a scrambled sequence with no match to any known gene) were selected based on the full-length cDNA of human TIMP-3 mRNA using a siRNA design software by Ambion (Table 1). A siRNA against GAPDH was included as a positive control to verify transfection reliability, RNA extraction and gene expression quantification. shRNAs (shTIMP-3, shNC and shPC) were synthesized and inserted into the pGPU6/GFP/Neo vector by Shanghai GenePharma Co., Ltd.

Construction of luciferase reporter plasmids

In luciferase reporter plasmids, the human TIMP-3 promoter sequences (from −702 to +18, relative to the transcription start site of the TIMP-3 gene) were synthesized and constructed into the pGL3-enhancer vector (Promega, Madison, WI, USA) by the Generay Company (Shanghai, China). All plasmids were confirmed by DNA sequencing. Luciferase reporter constructs containing wild-type or mutant promoter sequences were named pTIMP-3 (−702/+18), pTIMP-3 (mutP53), pTIMP-3 (mutFOXP1) and pTIMP-3 (mutE2F) (Fig 4(a)).
Transient transfection and luciferase assay

SPC-A1 and A549 cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with 4 μg of each constructed luciferase plasmid. Simultaneously, 10 ng pRL-SV40 per well was also transfected as an internal control to correct the transfection efficiency. Beforehand, cells were seeded on 24-well plates overnight to ensure 90%–95% confluence at the time of transfection. Then, 24 hours after transfection, transfected cells were treated with or without mAb NJ001 (100 ng/μL), and 48 hours after transfection, luciferase activity was measured by the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) and expressed as the ratio of firefly luciferase to Renilla luciferase activity. All experiments were performed in triplicate.

Electrophoretic mobility shift assay (EMSA)

Sense probe sequences were FOXP1 BS1 wild-type probe, 5’-AGAACTCTGTTTTGTTTTCTTCAT-3’; FOXP1 BS1 mutant probe, 5’-GAGCACAGAAAAACAGTCTTCTATC-3’; FOXPI BS2 wild-type probe, 5’-AGAACTCCCGGTCCGGTTCTTCAT-3’; FOXPI BS2 mutant probe, 5’-GAGCACAGAAGGGGTCTTCTATC-3’. Nuclear proteins were extracted with NE-PERTM Nuclear and Cytoplasmic Extraction Reagents (Pierce, Rockford, IL, USA). DNA probes were prepared with the Biotin 3’-End DNA Labeling Kit (Pierce). EMSA was performed with a LightShift Chemiluminescent EMSA Kit (Pierce). Binding reactions were performed with nuclear extracts (8 mg) and binding buffer with 2.5% glycerol, 5 mM MgCl2, 50 ng/mL poly (dI-dC), 0.05% NP-40, and 2 fmol biotin-labeled FOXP1 BS1/FOXP1 BS2 probes, which were incubated on ice for 30 minutes in a volume of 20 μL. For competition studies, nuclear extracts were incubated with unlabeled oligonucleotides for 30 minutes before adding the labeled oligonucleotides.

Tumor cells invasion assay

SPC-A1 and A549 cells were transfected with shTIMP-3 or treated with mAb NJ001 (0, 50, 100 and 150 ng/μL) for 48 hours. Cell invasiveness was quantified by counting cells that passed through the Matrigel membrane, using a light microscope (×200). Each experiment was performed three times. Data are expressed as the means ± s.d. *P < 0.05, **P < 0.01, compared with 0 ng/μL NJ001.
24 hours, then harvested and placed into transwell inserts that contained 500 μL of RPMI 1640 media plus 10% FBS in the lower chamber. After 24 hours, cells that had passed through the Matrigel membrane were stained with crystal violet and counted (8 high-power fields, ×200 magnification). Experiments were conducted in triplicate.

Wound-healing assay

SPC-A1 cells in six-well plates were cultured until monolayers formed. After being starved overnight, SPC-A1 cells were exposed to mitomycin C (10 μg/mL) for two hours. Cell layers were wounded using a 10 μL pipette tip and cultured with mAb NJ001 (0, 50, 100 or 150 ng/μL) for another 48 hours. Photographs were taken at 0 and at 48 hours. The distance traveled by the cells was measured between the two boundaries of the acellular area and the results of the treatment groups were expressed as a ratio to the control group cells. Each experiment was performed in triplicate.

Immunoelectron microscope

SPC-A1 and HFL1 cells were cultured in six well plates. The cells were fixed and stained over night with the mouse mAb NJ001 (1:400) in 2% normal goat serum, washed with 50 mM TBS and stained for 30 minutes with a gold-coupled antimouse antibody (1:50, Nanoprobes, Stony Brook, New York, USA). Samples were analyzed with a Zeiss Leo TEM. Briefly, pictures of cells were randomly taken, the regions of interest were outlined and the number of gold particles was counted within these regions. Non-treated, stained cells of the same culture dishes were taken as negative control.

Cytoplasmic, nuclear and membrane protein extraction

Treated SPC-A1 cells (treated with 200 ng/μL NJ001 for 48 hours) and control SPC-A1 cells were collected to extract cytoplasmic, nuclear and membrane protein using Compartmental Protein Extraction Kit (Millipore, Boston, Massachusetts, USA) according to the manufacturer’s recommendations. Cold buffer C was added to SPC-A1 cells and rotated at 4°C for 20 minutes. Following centrifugation (15 000 g for 20 minutes at 4°C), supernatants were kept as cytoplasmic proteins and pellets were washed once with buffer W. Cell pellets were then incubated in Buffer N and rotated at 4°C for 20 minutes. Following centrifugation (15 000 g for 20 minutes at 4°C), supernatants were kept as nuclear proteins and pellets were incubated in Buffer M to isolate membrane proteins.

Co-immunoprecipitation (Co-IP)

Co-IP was carried out using the Pierce Co-Immunoprecipitation Kit (Pierce, Rock-ford, Illinois, USA) according to the manufacturer’s recommendations. A total of 1 mg of nuclear protein of SPC-A1 treated with or without mAb NJ001 was incubated

| Table 2 Effect of mAb NJ001 on gene expression in SPC-A1 cells |
|---------------------------------|----------------|----------------|
| Full name | Gene | GeneBank | Fold change (NJ001/control) | Function |
| Metallopeptidase inhibitor 3 | TIMP-3 | NM_000362 | 2.0 | Extracellular matrix protein |
| Matrix metallopeptidase 7 | MMP-7 | NM_002423 | −2.1 | Extracellular matrix protein |

Figure 2 Effect of mAb NJ001 on downstream gene expression. (a) RT-qPCR analyses were used to validate TIMP-3 and MMP-7 expression. Data are expressed as the means ± s.d. *P < 0.001, compared with 0 ng/μL NJ001. (b) Western blots confirmed TIMP-3 expression regulated by mAb NJ001 in SPC-A1 cells. GAPDH was used as an internal control. Lower panel: relevant band densitometry analysis.
with equal amounts (3 μg) of FOXP1 antibody or normal rabbit IgG (Cell Signaling Technology Inc., Beverly, Massachusetts, USA) and protein A-Agarose preblocked with BSA. FOXP1 immunocomplexes eluted by nonreducing SDS buffer were resolved on 10% polyacrylamide gels and immunoblotted with mAb NJ001 (1:1000).

Statistical analysis
The results are expressed as mean ± s.d. Differences between experimental groups were analyzed with the χ² test. For single comparisons of two groups, Student’s t-test was used. P < 0.05 was considered statistically significant.

Results

MAb NJ001 inhibits migration and invasiveness of SPC-A1 cells

SPC-A1 cells were treated with mAb NJ001 for 48 hours. NJ001 slowed cell migration across the wound scratch in a dose dependent manner (Fig 1(a)). Quantitative analyses at 48 hours confirmed a significant reduction in wound closure in cells treated with 100 and 150 ng/μL NJ001 compared with the control cells (0 ng/μL NJ001) (Fig 1(b)).

To study the effect of mAb NJ001 on invasiveness in lung AD cells, we used a Matrigel model (Fig 1(c)). Movement by SPC-A1 and A549 cells treated with 150 ng/μL NJ001 was significantly impaired, by up to 65% at 24 hours (Fig. 1(d,e)).

MAb NJ001 increased expression of metastasis-related gene inhibitor of metalloproteinases 3 (TIMP-3) in SPC-A1 cells

To elucidate the mechanisms underlying the inhibitory effect of mAb NJ001 on lung AD cell invasiveness, we used an Affymetrix Human 1.0ST gene chip assay to analyze gene expression (GSE59655, https://www.ncbi.nlm.nih.gov/geo/). Compared with control cells, mAb
NJ001 altered downstream target genes matrix metalloproteinases 7 (MMP-7) and tissue inhibitor of metalloproteinases 3 (TIMP-3), both of which regulate cancer invasiveness and metastasis. MAb NJ001 increased the expression of TIMP-3 (2.0-fold) and suppressed MMP-7 (−2.1-fold) (Table 2).

To validate these gene chip results, quantitative PCR and western blot were performed on SPC-A1 cells treated with mAb NJ001 (at 0, 50, 100 or 150 ng/μL). MAb NJ001 significantly increased TIMP-3 and suppressed MMP-7 mRNA expression in SPC-A1 cells (Fig 2(a)). TIMP-3 protein expression was also enhanced by mAb NJ001 (Fig 2(b)), but MMP-7 protein could not be detected in SPC-A1 cells. Thus, TIMP-3 may play a larger part than MMP-7 did in inhibiting the invasiveness of mAb NJ001-treated lung AD cells.

**TIMP-3 mediates inhibition of invasiveness in mAb NJ001-treated lung AD**

To further determine the role of TIMP-3 in inhibiting invasiveness of mAb NJ001-treated lung AD cells, we developed SPC-A1 cells with endogenous TIMP-3 knockdown, using shTIMP-3. We selected SPC-A1 cells for the TIMP-3 silencing and tumor cell invasion assay because their endogenous TIMP-3 level is lower than that of human lung fibroblast cells (HFL1) (Fig 3(a)), which is similar to TIMP-3 expression in tumor cells from patients with lung cancer. At 48 hours after transfection with shRNA, expression of pGPU6/GFP/Neo which included a cassette of green fluorescent protein showed >60% transfection efficiency (Fig 3(b)), and expression of TIMP-3 mRNA was decreased.
by 70% (Fig 3(c)). In mAb NJ001-treated SPC-A1 cells, TIMP-3 knockdown successfully reversed the inhibitory effect of mAb NJ001 on cancer cell invasiveness (Fig 3(d,e)). The combination of mAb NJ001 and shTIMP-3 reduced the expression of both TIMP-3 mRNA and protein (Fig 3(f,g)).

**Transcriptional regulation of TIMP-3 by mAb NJ001**

To further determine whether the mAb NJ001-mediated change in TIMP-3 expression occurs on the transcriptional level, the TIMP-3 promoter region was analyzed using MatInspector software (Genomatrix Software GmbH, Munich, Germany). Four luciferase reporter plasmids containing wild-type TIMP-3 promoter sequences or P53/FOXP1/E2F binding site mutant sequences were synthesized (Fig 4(a)). Promoter binding sites for P53 and FOXP1 transcription factors are negative regulators of TIMP-3, whereas binding sites for E2F strongly enhance TIMP-3 activity. MAb NJ001 directly activates TIMP-3 transcription by suppressing the FOXP1 binding sites (Fig 4(b)). We performed EMSA in SPC-A1 cells (Fig 4(c)) and observed a strong protein–probe band to shift when the nuclear extracts were incubated with TIMP-3 BS1 or TIMP-3 BS2 wild biotin-labeled probes. The protein–probe band could not compete with mutant probes (Fig 4(c)). These findings suggest that mAb NJ001 directly regulates TIMP-3 expression on the transcription level.

**Mab NJ001 increased SP antigen binding to FOXP1 in cell nucleus**

To identify the subcellular location of NJ001 specific antigens, immunoelectron microscope was applied, and it showed that gold particles of NJ001 specific antigens were in cytoplasm and cell nucleus of SPC-A1 (Fig 5(a)). However, none of the gold particles were found in HFL1 cells (Fig 5(a)). Western blot confirmed that NJ001 specific antigens were located in the cytomembrane, cytoplasm, and cell nucleus, and the molecular weights of SP antigens were 120, 70 and 50 kDa respectively (Fig 5(b)). As FOXP1 is a transcriptional regulator, the interaction between NJ001 specific antigen and FOXP1 is unclear. Co-immunoprecipitation and western blot showed that the NJ001 specific antigens (about 50 kDa) were expressed in FOXP1 immune complexes in nucleus of NJ001 treated SPC-A1 cells (Fig 5(c)). These findings suggest that mAb NJ001 induces its specific antigens and FOXP1 to form the immune complexes in nucleus of LAD cells.

**Discussion**

NJ001 is a newly-developed monoclonal antibody that is specific to NSCLC. Our previous studies showed that mAb NJ001 has effective antitumor activity. However, the effect of mAb NJ001 on invasiveness and metastasis in lung AD is not well studied. Here, we showed that mAb NJ001 inhibited metastatic activity in lung AD cell lines (SPC-A1...
and A549), particularly in wound healing, cell migration and invasion. However, the molecular mechanisms of these effects in lung AD cells have not been previously explored. To elucidate the main regulators of NJ001-mediated inhibition of metastasis in lung AD, we used a cDNA microarray to study mAb NJ001-treated SPC-A1 cells; genes with significantly altered expression levels were then validated by qRT-PCR and immunoblotting. We found that the inhibition of invasiveness and migration in mAb NJ001-treated cells was mediated by upregulation of TIMP-3.

TIMP-3 is an important endogenous inhibitor of matrix metalloproteinases, and of angiogenesis. Decreased levels of TIMP-3 have been shown in various human malignancies including breast cancer, prostate cancer, gastric cancer, esophageal squamous cell carcinoma, endometrial cancer, and cholangiocarcinomas. Low TIMP-3 expression has been associated with a poor prognosis and nodal metastasis in various cancers. Unrelated to its inhibitory effect on metalloproteinases, TIMP-3 is thought to inhibit vascular epithelial growth factor (VEGF)-mediated angiogenesis by blocking the binding of VEGF to its receptor. TIMP-3 overexpression induces apoptosis in stromal cells. TIMP-3 also affects extracellular matrix signaling.

In the present study, upregulation of TIMP-3 expression in mAb NJ001-treated cells suggests it has a role in suppressing lung AD invasion and metastasis. We have shown that endogenous TIMP-3 knockdown reverses the inhibitory effect of mAb NJ001 on cancer cell invasiveness, which indicates that TIMP-3 is a key regulator of the antimetastatic function of mAb NJ001. To further investigate the regulatory mechanism of TIMP-3 by mAb NJ001, we investigated three transcription factor binding sites on the TIMP-3 gene promoter in SPC-A1 cells and found that P53 and FOXP1 negatively regulates TIMP-3 promoter activity, whereas E2F positively regulates TIMP-3 promoter activity. We have also shown that mAb NJ001 enhances the transcription of TIMP-3 by directly regulating TIMP-3 promoter activity via FOXP1 binding sites.

Forkhead Box P1 (FOXP1) is a widely expressed transcription factor that reportedly plays an important role in several types of solid tumors. FOXP1 is considered to be an oncogene in some malignancies. FOXP1 negatively influences the growth of various human cancer cell lines, demonstrating that it can act as a tumor suppressor. We found that FOXP1 inhibits TIMP-3 promoter activity in lung AD. It is a molecular target of mAb NJ001 in the regulation of TIMP-3 expression, further inhibiting tumor invasion.

In conclusion, mAb NJ001 suppresses lung AD cell migration and invasion in vitro, and these effects are mediated by TIMP-3. These results imply that mAb NJ001 could have clinical applications in preventing or treating metastatic lung adenocarcinoma.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No. 81672100, and 81371894) and the Key Laboratory for Laboratory Medicine of Jiangsu Province of China (ZDXKB2016005).

Disclosure

The authors declare no conflicts of interest.

References

1 Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448–57.
2 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
3 Travis WD. Pathology of lung cancer. Clin Chest Med 2011; 32: 669–92.
4 Liu J, Zhang W, Gu M et al. Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer. Cancer Med 2018; 7: 2925–33.
5 Pan S, Wang F, Huang P et al. The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics. PLOS One 2012; 7: e33009.
6 Chetty C, Lakka SS, Bhoopathi P, Kunigal S, Geiss R, Rao JS. Tissue inhibitor of metalloproteinase-3 (TIMP-3) suppresses tumor angiogenesis in matrix metalloproteinase-2-down-regulated lung cancer. Cancer Res 2008; 68: 4736–45.
7 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92: 827–39.
8 Mino N, Takenaka K, Sonobe M et al. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 2007; 95: 250–7.
9 Yang H, Li J, Guo J, Zhang S. [Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2012; 15: 202–7.
10 Qi JH, Dai G, Luthert P et al. S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis. J Biol Chem 2009; 284: 19927–36.
11 Qi JH, Ebrahem Q, Moore N et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407–15.
12 Lu Y, Roy S, Nuovo G et al. Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011; 286: 42292–302.
13 Shinojima T, Yu Q, Huang SK et al. Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics 2012; 7: 1279–89.
MAb NJ001 inhibits TIMP-3 in lung cancer

C. Gu et al.

14 Guan Z, Zhang J, Song S, Dai DQ. Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagn Pathol 2013; 8: 110.
15 Smith E, De Young NJ, Tian ZQ et al. Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol 2008; 14: 203–10.
16 Yu D, Zhou H, Xun Q et al. microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. Oncol Lett 2012; 3: 1221–6.
17 Selaru FM, Olaru AV, Kan T et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloprotease 3. Hepatology 2009; 49: 1595–601.
18 Mylona E, Magkou C, Giannopoulou I et al. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome. Breast Cancer Res 2006; 8: R57.
19 Gu P, Xing X, Tanzer M et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 2008; 10: 563–72.
20 Shovlin CL, Scott J. Inherited diseases of the vasculature. Annu Rev Physiol 1996; 58: 483–507.
21 Matthews FJ, Cook SD, Majid MA, Dick AD, Smith VA. Changes in the balance of the tissue inhibitor of matrix metalloproteinases (TIMPs)-1 and -3 may promote keratocyte apoptosis in keratoconus. Exp Eye Res 2007; 84: 1125–34.
22 Finan KM, Hodge G, Reynolds AM et al. In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer 2006; 53: 273–84.
23 Kallio JP, Hopkins-Donaldson S, Baker AH, Kähäri VM. TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. Int J Cancer 2011; 128: 991–6.
24 Tan LZ, Song Y, Nelson J, Yu YP, Luo JH. Integrin alpha7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells. Am J Pathol 2013; 183: 831–40.
25 Koon HB, Ippolito GC, Banham AH et al. FOXP1: A potential therapeutic target in cancer. Expert Opin Ther Targets 2007; 11: 955–65.
26 Green MR, Gandhi MK, Courtney MJ, Marlton P, Griffiths L. Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in follicular lymphoma. Leuk Res 2009; 33: 1699–702.
27 Banham AH, Beasley N, Campo E et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 2001; 61: 8820–9.
28 Wang B, Weidenfeld J, Lu MM et al. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development, 2004; 131: 4477–87.
29 Hu H, Wang B, Borde M et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol 2006; 7: 819–26.
30 Shu W, Lu MM, Zhang Y, Tucker PW, Zhou D, Morrisey EE. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development 2007; 134: 1991–2000.
31 Li C, Tucker PW. DNA-binding properties and secondary structural model of the hepatocyte nuclear factor 3/fork head domain. Proc Natl Acad Sci USA 1993; 90: 11583–7.
32 Aster J, Kutok J. Complexity made simple in diffuse large B-cell lymphoma. Clin Cancer Res 2009; 15: 5291–3.
33 Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520–5.
34 Adams H, Tzankov A, Lugli A, Zlobec I. New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. J Clin Pathol 2009; 62: 986–97.
35 Hoeller S, Schneider A, Haralambieva E et al. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology. 2010; 57: 73–80.